Novel approaches for targeting BRCA2-deficient tumour cells by Tacconi, E

How homologous recombination maintains telomere integrity by Tacconi, E, Tarsounas, M

A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. by Chaikuad, A, Tacconi, E, Zimmer, J, Liang, Y, Gray, N, Tarsounas, M, Knapp, S

Targeting BRCA1 and BRCA2 deficiencies with G-quadruplex-interacting compounds by Zimmer, J, Tacconi, E, Folio, C, Badie, S, Porru, M, Klare, K, Tumiati, M, Markkanen, E, Halder, S, Ryan, A, Jackson, S, Ramadan, K, Kuznetsov, S, Biroccio, A, Sale, J, Tarsounas, M

Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma by McGowan, D, Skwarski, M, Bradley, K, Campo, L, Fenwick, J, Gleeson, F, Green, M, Horne, A, Maughan, T, McCole, M, Mohammed, S, Muschel, R, Ng, S, Panakis, N, Prevo, R, Strauss, V, Stuart, R, Tacconi, E, Vallis, K, McKenna, W, Macpherson, R, Higgins, G

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity. by Tacconi, E, Lai, X, Folio, C, Porru, M, Zonderland, G, Badie, S, Michl, J, Sechi, I, Rogier, M, Matía García, V, Batra, A, Rueda, O, Bouwman, P, Jonkers, J, Ryan, A, Reina-San-Martin, B, Hui, J, Tang, N, Bruna, A, Biroccio, A, Tarsounas, M

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance by Tacconi, E, Badie, S, De Gregoriis, G, Reisländer, T, Lai, X, Porru, M, Folio, C, Moore, J, Kopp, A, Baguña Torres, J, Sneddon, D, Green, M, Dedic, S, Lee, J, Batra, A, Rueda, O, Bruna, A, Leonetti, C, Caldas, C, Cornelissen, B, Brino, L, Ryan, A, Biroccio, A, Tarsounas, M